Neuralink Secures $650M in Series E Funding Led by Elon Musk
▼ Summary
– Neuralink raised $650 million in a Series E funding round, with investors including ARK Invest and Sequoia Capital.
– The company previously secured $280 million in a Series D round in 2023, followed by an additional $43 million.
– Neuralink has implanted its brain chips in five individuals with severe paralysis as part of human clinical trials.
– In May, Neuralink received breakthrough device designation from the FDA to accelerate development of its experimental technology.
– The latest funding round reportedly values Neuralink at approximately $9 billion pre-money.
Neuralink has secured $650 million in its latest funding round, marking a major milestone for Elon Musk’s ambitious brain-computer interface venture. The Series E investment, led by prominent backers including ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital, comes just over a year after the company’s previous $280 million raise in 2023.
This fresh capital injection arrives as Neuralink makes tangible progress in human trials. The company has successfully implanted its breakthrough brain chip technology in five patients suffering from severe paralysis. Earlier this year, the U.S. Food and Drug Administration (FDA) granted Neuralink breakthrough device status, accelerating regulatory pathways for further testing and commercialization.
Industry reports suggest the latest funding round values Neuralink at approximately $9 billion pre-money, underscoring growing investor confidence in its potential to revolutionize neurotechnology. The company aims to push boundaries in restoring mobility and communication for individuals with neurological conditions while exploring broader applications for human-machine integration.
With this financial boost, Neuralink is poised to expand clinical trials, refine its implantable devices, and potentially bring its futuristic vision closer to reality. The funding also signals strong market interest in brain-computer interfaces as a transformative frontier in medical and technological innovation.
(Source: TechCrunch)
